Yeshwant Krishna 4

What Happened

• Yeshwant Krishna, a director of Parabilis Medicines, was granted a derivative award covering 20,215 shares on June 9, 2026. The award was reported as acquired at $0.00 (i.e., no cash paid). This is a grant of an equity-based award (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-06-09; Form 4 filed: 2026-06-11 (filed within the standard 2-business-day window).
• Transaction type: Award/Grant (derivative instrument) — 20,215 shares, $0.00 per share reported.
• Vesting: The shares underlying the award vest in full upon the earlier of (i) June 9, 2027 or (ii) the issuer’s next annual meeting of stockholders, subject to Krishna’s continued service on the vesting date (per footnote).
• Shares owned after transaction: Not specified in the filing.
• No indication of a sale, exercise-for-cash, or tax-withholding action in this filing.

Context

• This is a typical compensation/retention award to an insider. It does not transfer actual stock today — the shares become beneficially owned only if/when the award vests and converts into shares (or is exercised, if it’s an option). Such grants are routine for directors and do not by themselves signal immediate buying or selling intent.